Association between the efcacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: A retrospective study

The combination of immune-checkpoint inhibitors with chemotherapy has become the standard of treatment for non-small cell lung cancer (NSCLC) patients. However, the association between therapeutic efcacy and the development of immune-related adverse events (irAEs) remains unclear in patients treated with combination therapy.